Scienture Holdings (SCNX)
NASDAQ:SCNX
Top Page
Scienture Holdings
(NASDAQ:SCNX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.31
▼(-43.45% Downside)
Action:ReiteratedDate:04/07/26
The score is driven primarily by weak financial performance: severe operating losses and persistent cash burn outweigh a currently manageable leverage profile. Technicals reinforce the risk with a clear downtrend and negative momentum. Valuation is constrained by a negative P/E and lack of dividend support.
Positive Factors
Manageable Leverage
Current low debt relative to equity gives the company near-term financial flexibility and reduces immediate refinancing risk. This supports the ability to fund operations or strategic initiatives over the next several months without forcing distress-driven capital raises, a durable balance-sheet advantage.
Negative Factors
Consistent Negative Cash Flow
Persistent, deep negative operating and free cash flow means the business does not self-fund and remains dependent on external financing. That structural cash-burn profile raises dilution and refinancing risk and constrains investments in growth or product development over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Current low debt relative to equity gives the company near-term financial flexibility and reduces immediate refinancing risk. This supports the ability to fund operations or strategic initiatives over the next several months without forcing distress-driven capital raises, a durable balance-sheet advantage.
Read all positive factors
Scienture Holdings (SCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.53M
Dividend YieldN/A
Average Volume (3M)4.08M
Price to Earnings (P/E)―
Beta (1Y)3.33
Revenue Growth-73.18%
EPS Growth92.38%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-490.22
Enterprise Value/Revenue-15.37K
Enterprise Value/Gross Profit-20.99K
Enterprise Value/Ebitda170.37
Forecast
1Y Price Target
$1.50Price Target Upside172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scienture Holdings Business Overview & Revenue Model
Company Description
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, h...
How the Company Makes Money
null...
Scienture Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 431.61K | 136.64K | 1.36M | 10.25M | 9.89M |
| Gross Profit | -160.30K | 6.00K | 49.03K | 5.52M | 4.75M |
| EBITDA | -38.93M | -17.39M | -6.29M | -1.87M | -5.15M |
| Net Income | -41.51B | 9.07M | -17.84M | -3.47M | -5.32M |
Balance Sheet | |||||
| Total Assets | 84.18B | 104.85M | 12.53M | 3.71M | 5.77M |
| Cash, Cash Equivalents and Short-Term Investments | 6.66B | 308.10K | 314.00 | 1.09M | 3.12M |
| Total Debt | 24.14M | 3.53M | 6.76M | 1.58M | 1.25M |
| Total Liabilities | 14.06B | 25.78M | 11.99M | 3.37M | 2.00M |
| Stockholders Equity | 70.12B | 79.07M | 542.35K | 763.14K | 3.77M |
Cash Flow | |||||
| Free Cash Flow | -13.38B | -14.28M | -2.23M | -1.56M | -2.59M |
| Operating Cash Flow | -13.38B | -14.27M | -2.23M | -1.56M | -2.57M |
| Investing Cash Flow | 0.00 | 27.55M | -275.72K | -427.85K | -22.60K |
| Financing Cash Flow | 19.73B | -12.98M | 1.41M | -35.17K | -208.18K |
Scienture Holdings Technical Analysis
Negative
0.55
Price Trends
0.41
Negative
0.48
Negative
0.85
Negative
Market Momentum
-0.03
Positive
41.53
Neutral
49.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNX, the sentiment is Negative. The current price of 0.55 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.41, and below the 200-day MA of 0.85, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.53 is Neutral, neither overbought nor oversold. The STOCH value of 49.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNX.
Scienture Holdings Risk Analysis
Scienture Holdings disclosed 76 risk factors in its most recent earnings report. Scienture Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scienture Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $13.53M | ― | -44.11% | ― | -73.18% | 92.38% | |
| ― | $7.65M | -1.95 | -8.26% | ― | -24.64% | 92.19% | |
42 Neutral | $10.89M | -0.51 | 336.68% | ― | 187.24% | 82.90% | |
41 Neutral | $2.77M | >-0.01 | -112.81% | ― | -21.88% | 68.40% |
* Healthcare Sector Average
SCNX
Scienture Holdings
0.33
-0.55
-62.16%
ZCMD
Zhongchao
1.99
-8.17
-80.41%
HCTI
Healthcare Triangle
2.40
-3,181.31
-99.92%
VSEE
VSee Health
0.23
-0.84
-78.50%
MGRX
Mangoceuticals, Inc.
0.34
-1.48
-81.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.